31 May 2018 
EMA/CHMP/283640/2018  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (initial authorisation) 
Aimovig 
erenumab 
On 31 May 2018, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive 
opinion, recommending the granting of a marketing authorisation for the medicinal product Aimovig, 
intended for prophylaxis of migraine. The applicant for this medicinal product is Novartis Europharm 
Limited. 
Aimovig will be available as a 70-mg solution for injection. The active substance of Aimovig is erenumab, 
an analgesic that works by binding to calcitonin gene-related peptide (CGRP) receptors (ATC code: 
N02CX07). 
The benefits with Aimovig are its ability to reduce number of monthly migraine days. The most common 
side effects are injection site reactions, constipation, muscle spasms and pruritus.  
The full indication is: “Aimovig is indicated for prophylaxis of migraine in adults who have at least 
4 migraine days per month”.  
It is proposed that Aimovig be prescribed by physicians experienced in the diagnosis and treatment of 
migraine.  
Detailed recommendations for the use of this product will be described in the summary of product 
characteristics (SmPC), which will be published in the European public assessment report (EPAR) and 
made available in all official European Union languages after the marketing authorisation has been 
granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5520 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 
 
  
 
 
 
  
                                                
